Format

Send to

Choose Destination
Cancer Sci. 2015 Oct;106(10):1341-50. doi: 10.1111/cas.12762.

Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway.

Li M1,2,3, Zhang F1,2,3, Wang X1,2,3, Wu X1,2,3, Zhang B4, Zhang N4, Wu W1,2,3, Wang Z1,2,3, Weng H1,2,3, Liu S1,2,3, Gao G4, Mu J1,2,3, Shu Y1,2,3, Bao R1,2,3, Cao Y1,2,3, Lu J1,2,3, Gu J1,2,3, Zhu J1,2,3, Liu Y1,2,3.

Author information

1
Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong, University School of Medicine, Shanghai, China.
2
Laboratory of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong, University School of Medicine, Shanghai, China.
3
Institute of Biliary Tract Disease, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
4
Department of General Surgery, Shanxi Medical University Second Hospital, Taiyuan, China.

Abstract

Magnolol, the major active compound found in Magnolia officinalis has a wide range of clinical applications due to its anti-inflammation and anti-oxidation effects. This study investigated the effects of magnolol on the growth of human gallbladder carcinoma (GBC) cell lines. The results indicated that magnolol could significantly inhibit the growth of GBC cell lines in a dose- and time-dependent manner. Magnolol also blocked cell cycle progression at G0 /G1 phase and induced mitochondrial-related apoptosis by upregulating p53 and p21 protein levels and by downregulating cyclin D1, CDC25A, and Cdk2 protein levels. When cells were pretreated with a p53 inhibitor (pifithrin-a), followed by magnolol treatment, pifithrin-a blocked magnolol-induced apoptosis and G0 /G1 arrest. In vivo, magnolol suppressed tumor growth and activated the same mechanisms as were activated in vitro. In conclusion, our study is the first to report that magnolol has an inhibitory effect on the growth of GBC cells and that this compound may have potential as a novel therapeutic agent for the treatment of GBC.

KEYWORDS:

Apoptosis; cell cycle arrest; gallbladder carcinoma; magnolol; p53 pathways

PMID:
26250568
PMCID:
PMC4638010
DOI:
10.1111/cas.12762
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center